Contents

| | Page |
|-----------------------|----------|
| Abstract | i |
| Acknowledgements | iii |
| Contents | v-vi |
| List of Figures | vii-viii |
| List of Tables | ix |
| List of Symbols | х |
| List of Abbreviations | xi-xii |

Chapter 1: INTRODUCTION

| 1.1 | Purpose of the Study | 1 |
|-----|---|---|
| 1.2 | An Outline of the Results and Future Perspectives of the Present Work | 2 |
| | 1.2.1 Lanosterol Suppresses the Aggregation and Cytotoxicity of Misfolded Proteins Linked with Neurodegenerative Diseases | 2 |
| | 1.2.2 Ibuprofen Induces Mitochondrial-Mediated Apoptosis through Proteasomal Dysfunction | 3 |

Chapter 2: Review of Literature

| 2.1 | A Glimpse of Cellular Protein Quality Control Systems | 5-10 |
|-----|---|-------|
| | 2.1.1 Molecular chaperones | 6 |
| | 2.1.2 Cellular Proteolytic Machinery: Ubiquitin proteasome system and Autophagy | 6 |
| 2.2 | Deficiency of Cellular Quality Control and Pathological Conditions | 10 |
| 2.3 | Characteristics of Amyloidic Aggregates and Inclusion bodies | 11 |
| | 2.3.1 Unique Structural Properties of Amyloids | 12 |
| 2.4 | Cellular Protein Quality Control Pathways and a Possible Linkage between Neurodegeneration and Cancer | 13 |
| 2.5 | Modulating Protein Qualtiy Control Pathways for Therapeutic Purposes | 14-18 |
| | 2.5.1 Methods to Suppress Amyloid Formation | 15 |
| | 2.5.2 Small Molecules | 17 |
| 2.6 | Concluding Remarks | 18 |

Chapter 3: Lanosterol Suppresses the Aggregation and Cytotoxicity of Misfolded Proteins Linked with Neurodegenerative Diseases

| Results | 21-44 |
|--|---|
| 3.1.1 Lanosterol Induces Protective Autophagy and Upregulation of Endogenous Co- | 21 |
| Chaperone CHIP Expression in Cells | |
| 3.1.2 Lanosterol Prevents Cytoplasmic Aggregation of Mutant Bona-fide Misfolded Proteins in | 24 |
| Cells | |
| 3.1.3 Lanosterol Enhances the Degradation of Heat-Denatured Luciferase | 27 |
| 3.1.4 Effects of Lanosterol on Neurodegenerative Disease-Linked Proteins | 29 |
| 3.1.5 Lanosterol Increases the Stability of Co-Chaperone CHIP | 33 |
| 3.1.6 Lanosterol Diminishes Aggregation of Expanded Polyglutamine Proteins in Cells | 35 |
| 3.1.7 Lanosterol Rescues Stress-Induced Cell Death and Suppresses Aggregation of Deleterious | 40 |
| Intracellular Protein Aggregation | |
| Discussion | 42 |
| Concluding Remarks | 44 |
| | |
| er 4: Ibuprofen Induces Mitochondrial-Mediated Apoptosis through Proteasomal | |
| nction | |
| | 3.1.1 Lanosterol Induces Protective Autophagy and Upregulation of Endogenous Co-Chaperone CHIP Expression in Cells 3.1.2 Lanosterol Prevents Cytoplasmic Aggregation of Mutant Bona-fide Misfolded Proteins in Cells 3.1.3 Lanosterol Enhances the Degradation of Heat-Denatured Luciferase 3.1.4 Effects of Lanosterol on Neurodegenerative Disease-Linked Proteins 3.1.5 Lanosterol Increases the Stability of Co-Chaperone CHIP 3.1.6 Lanosterol Diminishes Aggregation of Expanded Polyglutamine Proteins in Cells 3.1.7 Lanosterol Rescues Stress-Induced Cell Death and Suppresses Aggregation of Deleterious Intracellular Protein Aggregation Discussion Concluding Remarks |

| 4.1 | Results | 47-67 |
|-----|---|-------|
| | 4.1.1 Ibuprofen Treatment Causes Accumulation of Ubiquitylated Proteins and Induces Time- | 47 |
| | Dependent Morphological Apoptotic Changes | |
| | 4.1.2 Treatment of Ibuprofen Disturbs Proteasomal Function and Induces Rapid Accumulation | 50 |
| | of Misfolded Proteins | |
| | 4.1.3 Ibuprofen-Mediated Interference Can Contribute in Proteasomal Inhibition-Induced | 55 |

| | Cytotoxicity | |
|-------|--|-------|
| | 4.1.4 Ibuprofen Induces Proteasomal Dysfunction, Facilitates Formation of Inclusions of | 57 |
| | Misfolded Proteins, and Elevates Aggregation of Proteasomal Substrates | |
| | 4.1.5 Ibuprofen Compromises the Clearance of Pro-Apoptotic Ubiquitinated Proteins Destined | 59 |
| | for Proteasomal Degradation | |
| | 4.1.6 Ibuprofen-Mediated Proteasomal Disturbance Triggers Chromatin Condensation, Nuclear Disassembly, and DNA Fragmentation and Activates Cell Death Program | 61 |
| | 4.1.7 Ibuprofen Induces Loss of Mitochondrial Membrane Potential and Release of | 63 |
| | Cyctochrome c | , |
| 4.2 | Discussion | 65 |
| 4.3 | Concluding Remarks | 67 |
| | | |
| Chapt | ter 5: Summary and Conclusion | |
| 5.1 | Summary | 69 |
| 5.2 | Conclusion | 69 |
| 5.3 | Closing comments | 70 |
| Annex | kure A: Materials and Methods | |
| A.1 | Materials | 7374 |
| | A.1.1 Cell Lines | 74 |
| A.2 | Methods | 74-77 |
| | A.2.1 Large Scale Plasmid Extraction | 74 |
| | A.2.2 Cell Culture, Transfection, and Drug Treatments | 74 |
| | A.2.3 Cell Viability Assay | 75 |
| | A.2.4 SDS-PAGE and Immunoblotting | 75 |
| | A.2.5 Cycloheximide Chase Experiment | 75 |
| | A.2.6 Immunofluorescence Techniques and Counting of Aggregates | 75 |
| | A.2.7 Reverse Transcriptase PCR Analysis, Quantitative Real-Time RT-PCR Analysis | 75 |
| | A.2.8 Proteasome Assay | 76 |
| | A.2.9 Flow Cytometry Analysis | 76 |
| | A.2.10 Molecular Docking Studies | 76 |
| | A.2.11 JC-1 Staining | 76 |
| | A.2.12 Reporter Gene Assay and Statistical Analyses | 77 |
| | A.2.13 TUNEL Assay and Filter Trap Assay | 77 |
| | A.2.14 Extraction of Genomic DNA and Agarose Gel Electrophoresis | 77 |
| | | |

References

79-95